Retatrutide FDA approval is not yet granted. Learn the latest on its phase 3 trials, expected timeline, legal status in the US, and availability.
Retatrutide is not FDA-approved for any medical use in the United States as of early 2025. It remains an investigational drug, meaning it is only legally available to participants in ongoing clinical trials. No approved retatrutide product exists for weight loss, type 2 diabetes, or any other condition.
What Is Retatrutide and How Does It Work?
Retatrutide is an experimental triple agonist developed by Eli Lilly. It targets three hormone receptors: GLP-1, GIP, and glucagon. This triple action is designed to increase energy expenditure and reduce appetite more than existing GLP-1 drugs.
Early phase 2 trial results showed significant weight loss in participants with obesity. However, these findings do not guarantee FDA approval. The drug must still complete large phase 3 trials and undergo a full regulatory review.
Current Retatrutide FDA Approval Status
As of February 2025, retatrutide has not received FDA approval. The FDA has not even accepted a New Drug Application (NDA) for retatrutide. The drug is currently in phase 3 clinical trials under the TRIUMPH program.
The TRIUMPH program includes several phase 3 trials, such as TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3. These trials are testing retatrutide in people with obesity, type 2 diabetes, and related conditions. Results are expected between 2025 and 2026.
For a drug to gain FDA approval, it must demonstrate safety and efficacy in rigorous trials. Retatrutide is years away from a potential approval decision. The question "is retatrutide fda-approved" currently has a simple answer: no.
Retatrutide is not approved in any country as of early 2025. It is not available for purchase as a prescription medication anywhere. The only legal way to access retatrutide is through a clinical trial.
Retatrutide Approval Timeline: When Will It Be Approved?
Most analysts expect a potential retatrutide approval in 2026 or 2027, assuming phase 3 trials succeed. Eli Lilly has not announced a specific submission date. The FDA review process itself typically takes 6 to 12 months after an NDA is filed.
Phase 3 trials for retatrutide are expected to complete in 2025 and 2026. After that, the company must compile and submit data. This means when is retatrutide going to be available is still an open question.
Even if trials succeed, the FDA may require additional studies or a risk evaluation and mitigation strategy (REMS). This can extend the timeline further. The agency often takes longer for drugs with novel mechanisms.
Is Retatrutide Legal in the US?
Retatrutide is not legal for human consumption in the United States. Because it is not FDA-approved, it cannot be prescribed or sold as a medication. Some online vendors sell retatrutide as a "research chemical," but this is not intended for human use.
Purchasing or using unapproved research chemicals carries serious risks. The product may be impure, incorrectly dosed, or contaminated. The FDA has not evaluated retatrutide for safety or effectiveness in humans.
The FDA has issued warnings about unapproved GLP-1 products sold online. These products may contain unknown ingredients or incorrect dosages. People have reported serious side effects from such products.
So, is retatrutide legal in the us? No, it is not legal to use as a drug. Possession for personal use is not explicitly banned by federal law in all cases, but selling it for human consumption is illegal.
Retatrutide vs. Other Weight Loss and Metabolic Drugs
Comparing retatrutide to approved and investigational options helps clarify its status. Below is a table of key differences.
| Drug | FDA Status | Mechanism | Approved for Weight Loss? | Notes |
|---|---|---|---|---|
| Retatrutide | Not approved; phase 3 trials | Triple agonist (GLP-1, GIP, glucagon) | No | Investigational |
| Tirzepatide (Zepbound) | Approved for weight loss | Dual agonist (GLP-1, GIP) | Yes | Brand name Zepbound |
| Semaglutide (Wegovy) | Approved for weight loss | GLP-1 agonist | Yes | Brand name Wegovy |
| Cagrilintide | Not approved; phase 3 trials | Amylin analog | No | Often studied with semaglutide |
| AOD-9604 | Not approved | HGH fragment | No | Sold as research chemical |
When people compare aod 9604 vs retatrutide, they find that neither is FDA-approved for weight loss. The question is aod-9604 fda approved also returns a negative answer. A three-way comparison of cagrilintide vs retatrutide vs tirzepatide shows that only tirzepatide is currently approved.
Some researchers also explore cjc 1295 ipamorelin with retatrutide in non-clinical settings, but no approved combination exists. The ss 31 fda approval process is unrelated, but it illustrates how long regulatory reviews can take.
Tirzepatide and semaglutide are approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. They are not approved for cosmetic weight loss. Insurance coverage varies, and both require a prescription.
Safety, Side Effects, and What to Do Next
Retatrutide's side effect profile is still being characterized. In phase 2 trials, common side effects included:
- Nausea
- Diarrhea
- Vomiting
- Constipation
These are similar to other GLP-1 drugs. Because retatrutide is not approved, no medical professional can legally prescribe it. Anyone considering retatrutide should wait for FDA approval or enroll in a clinical trial.
Retatrutide may also cause gallbladder problems, pancreatitis, and allergic reactions. These risks are similar to other GLP-1 drugs. Long-term safety data are not yet available.
Consulting a healthcare provider is essential before using any weight loss drug. For now, approved options like tirzepatide and semaglutide are available for eligible patients. These drugs have known safety profiles and clear dosing guidelines. Retatrutide may join them in the future, but that depends on ongoing trials.
Frequently Asked Questions
Is retatrutide FDA-approved?
No, retatrutide is not FDA-approved as of early 2025. It is still in phase 3 clinical trials and has not been submitted for FDA review.
When will retatrutide be available?
If phase 3 trials are successful, retatrutide could be approved in 2026 or 2027. However, no official timeline has been confirmed by Eli Lilly or the FDA.
Is retatrutide legal to buy in the US?
It is not legal to buy retatrutide for human consumption because it is not FDA-approved. Some vendors sell it as a research chemical, but these products are not regulated and may be unsafe.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.